Cancer is a molecular disease associated with alterations in the genome, which, thanks to
the highly improved sensitivity of mutation detection techniques, can be identified in cell-free
DNA (cfDNA) circulating in blood, a method also called liquid biopsy. This is a non-invasive
alternative to surgical biopsy and has the potential of revealing the molecular signature of
tumors to aid in the individualization of treatments. In this review, we focus on cfDNA
analysis, its advantages, and clinical applications employing genomic tools (NGS and …